Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA PET/CT in Prostate Cancer
NCT03001869Phase 3Completed
- Sponsor
- Jewish General Hospital
- Start
- Jul 2017
- Primary completion
- Jul 2023
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by Jewish General Hospital. Started Jul 2017; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03001869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001869.